Viridian Therapeutics Inc (NASDAQ:VRDN) — Market Cap & Net Worth
Market Cap & Net Worth: Viridian Therapeutics Inc (VRDN)
Viridian Therapeutics Inc (NASDAQ:VRDN) has a market capitalization of $1.71 Billion ($1.71 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6748 globally and #2102 in its home market, demonstrating a -3.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Viridian Therapeutics Inc's stock price $22.44 by its total outstanding shares 103074740 (103.07 Million). Also see Viridian Therapeutics Inc assets under control for a full breakdown of the balance sheet.
Viridian Therapeutics Inc Market Cap History: 2015 to 2026
Viridian Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $17.35 Billion to $2.31 Billion (-18.52% CAGR). Also see Viridian Therapeutics Inc (VRDN) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
Viridian Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.06% | #194 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #757 of 3165 |
Weight: Viridian Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Viridian Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Viridian Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check VRDN stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
45.27x
Viridian Therapeutics Inc's market cap is 45.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $7.75 Billion | $3.34 Million | -$12.67 Million | 2321.27x | N/A |
| 2017 | $16.13 Billion | $4.00 Million | -$26.51 Million | 4028.49x | N/A |
| 2018 | $4.68 Billion | $8.39 Million | -$32.70 Million | 558.64x | N/A |
| 2019 | $741.98 Million | $4.46 Million | -$41.87 Million | 166.33x | N/A |
| 2020 | $1.70 Billion | $1.05 Million | -$110.72 Million | 1614.84x | N/A |
| 2021 | $2.04 Billion | $2.96 Million | -$79.41 Million | 687.74x | N/A |
| 2022 | $3.01 Billion | $1.77 Million | -$129.87 Million | 1699.10x | N/A |
| 2023 | $2.24 Billion | $314.00K | -$237.73 Million | 7149.58x | N/A |
| 2024 | $1.98 Billion | $302.00K | -$269.95 Million | 6542.86x | N/A |
| 2025 | $3.21 Billion | $70.85 Million | -$342.60 Million | 45.27x | N/A |
Competitor Companies of VRDN by Market Capitalization
Companies near Viridian Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review Viridian Therapeutics Inc tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Viridian Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Viridian Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Viridian Therapeutics Inc's market cap moved from $17.35 Billion to $ 2.31 Billion, with a yearly change of -18.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.31 Billion | -27.89% |
| 2025 | $3.21 Billion | +62.34% |
| 2024 | $1.98 Billion | -11.98% |
| 2023 | $2.24 Billion | -25.44% |
| 2022 | $3.01 Billion | +47.75% |
| 2021 | $2.04 Billion | +20.18% |
| 2020 | $1.70 Billion | +128.52% |
| 2019 | $741.98 Million | -84.16% |
| 2018 | $4.68 Billion | -70.95% |
| 2017 | $16.13 Billion | +108.18% |
| 2016 | $7.75 Billion | -55.35% |
| 2015 | $17.35 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Viridian Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.71 Billion USD |
| MoneyControl | $1.71 Billion USD |
| MarketWatch | $1.71 Billion USD |
| marketcap.company | $1.71 Billion USD |
| Reuters | $1.71 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develo… Read more